ClinicalTrials.gg
RecruitingNCT07286058Updated Nov 12, 2026

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

A Phase 3 interventional study of Zasocitinib in Psoriatic Arthritis, sponsored by Takeda. Recruiting at 111 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 12, 2026First sites in 4 new countries33 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
5th of 158
1,182 · median 237
Started
2026
with 7 others
Phase 3
71 of 193
4 open now
Primary completion
2029-12
later than 50 of 58 live
Registered
187th of 193
by date

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 5th largest by planned enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2026, is one of 71 in phase 3, reaches primary completion later than 50 of the 58 other live ones, and was the 187th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.

The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.

Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 [NCT06671483] or TAK-279-PsA-3002 [NCT06671496]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).

Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Drug Therapy
  • Latitude PsA
  • Latitude PsA-3003
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is aged 18 years or older at the time of signing the form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age.
  2. The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies.
  3. The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy.

Exclusion criteria

Exclusion Criteria:

  1. Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study.
  2. Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002).
  3. The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
  4. The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,182 participants (estimated)

Study arms

  • Experimental
    Zasocitinib Dose A or Dose B

    Participants assigned to zasocitinib in the either parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) will continue to receive zasocitinib Dose A or Dose B at the same dose, oral tablets, QD for up to Week 104.

    Drug: Zasocitinib

  • Experimental
    Re-randomized Participants - Zasocitinib Dose A or Dose B

    Participants assigned to active comparator in the parent study (TAK-279-PsA-3001 \[NCT06671483\]) will be re-randomized to blinded treatment with zasocitinib Dose A or Dose B, oral tablets, QD for up to Week 104.

    Drug: Zasocitinib

Interventions

  • Zasocitinib oral tablets.

    Also known as: TAK- 279, NDI-034858

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. TEAE is defined as any AE emerging or manifesting at or after the initiation of treatment in the LTE study with a trial intervention or medicinal product or any existing AE that worsens in either intensity or frequency following exposure to the trial intervention or medicinal product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event.

    Time frame: From start of study drug administration up to follow-up (up to Week 108)

  2. Number of Participants With Adverse Events of Special Interest (AESI)

    An AESI is an adverse event of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator may be appropriate.

    Time frame: From start of study drug administration up to follow-up (up to Week 108)

  3. Number of Participants With Clinically Significant Changes in Vital Sign Values

    Vital signs will include measurement of body temperature, respiratory rate, sitting blood pressure and pulse rate. Any clinically significant change in vital signs will be determined at the investigator's discretion.

    Time frame: From start of study drug administration up to follow-up (up to Week 108)

  4. Number of Participants With Clinically Significant Changes in Clinical Laboratory Values

    Laboratory parameters will include hematology, chemistry and urinalysis. Any clinically significant change in laboratory values will be determined at the investigator's discretion.

    Time frame: From start of study drug administration up to follow-up (up to Week 108)

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology (ACR20) Response at Weeks 24, 48, and 104

    ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite clinical outcome assessment (COA) measure that includes both clinician-reported outcome assessments (ClinROs) and patient-reported outcomes (PROs). An ACR20 response is defined as greater than or equal to (\>=) 20 percentage (%) improvement from baseline in both swollen joint count 66 joints (SJC66) and tender joint count 68 joints (TJC68), and \>=20% improvement from baseline in 3 of the following 5 assessments: Patient's global assessment (PtGA) of PsA pain; PtGA of PsA; physician's global assessment of disease activity (PGA) of PsA; participant's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-DI); high-sensitivity C-reactive protein (hsCRP).

    Time frame: At Weeks 24, 48, and 104

  2. Percentage of Participants Achieving ACR50 at Weeks 24, 48, and 104

    ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite COA measure that includes both ClinROs) and PROs. An ACR50 response is defined as \>=50% improvement from baseline in both SJC66 and TJC68, and \>=50% improvement from baseline in 3 of the following 5 assessments: PtGA of PsA pain; PtGA of PsA; PGA of PsA; participant's assessment of physical function as measured by HAQ-DI; hsCRP.

    Time frame: At Weeks 24, 48, and 104

  3. Percentage of Participants Achieving ACR70 at Weeks 24, 48, and 104

    ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite COA measure that includes both ClinROs) and PROs. An ACR70 response is defined as \>=70% improvement from baseline in both SJC66 and TJC68, and \>=70% improvement from baseline in 3 of the following 5 assessments: PtGA of PsA pain; PtGA of PsA; PGA of PsA; participant's assessment of physical function as measured by HAQ-DI; hsCRP.

    Time frame: At Weeks 24, 48, and 104

  4. Percentage of Participants Achieving Minimal Disease Activity (MDA) Status at Weeks 24, 48, and 104

    The MDA is defined as a composite outcome measure of 7 ClinROs and PROs used in PsA. Participants are classified as achieving MDA if they fulfil 5 of 7 outcome measures: TJC68 less than or equal to (\<=) 1, SJC66 \<=1, psoriasis area and severity index (PASI) score \<=1 or body surface area (BSA) affected by psoriasis (PsO) \<=3%, PtGA of PsA Pain score \<=15, PtGA of PsA score \<=20, HAQ-DI \<=0.5, and Leeds Enthesitis Index (LEI) \<=1.

    Time frame: At Weeks 24, 48, and 104

  5. Percentage of Participants Achieving >=75 % Improvement From Baseline in PASI Score at Weeks 24, 48, and 104

    A PASI-75 response is defined as \>=75% improvement in the PASI score from baseline. It is a ClinRO used to measure PsO severity, combining the percentage of surface area of skin affected with the severity of erythema, induration, and desquamation across four body regions: head, upper extremities, trunk, and lower extremities. Severity is scored on a 0-4 scale, with 0 indicating a complete lack of cutaneous involvement and 4 indicating the severest possible involvement. PASI scores range from 0 to 72, with \<=3 representing mild disease, \>=3 to 15 representing moderate disease, and \>=15 indicating severe disease.

    Time frame: At Weeks 24, 48, and 104

07

Study locations

111 of 111 sites recruiting

Showing the first 100 of 111 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 45 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 16, 2025
StartActual
Mar 11, 2026
Primary completionEst.
Dec 18, 2029
CompletionEst.
Dec 18, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
33 sites added — first sites in Argentina, Chile, Italy and United Kingdom
Show 33 added (5 China, 5 Poland, 4 United States, 3 Chile, 3 Spain, 2 Hungary, 2 Japan, 1 Argentina, 1 Australia, 1 Croatia, 1 Czechia, 1 Estonia, 1 Italy, 1 New Zealand, 1 Taiwan, 1 United Kingdom)
  • Bioresearch Partners · Miami, United States
  • Clinical Research of West Florida | Tampa · Tampa, United States
  • Michigan Rheumatology Group, P.C. - Grand Blanc Office · Grand Blanc, United States
  • DJL Clinical Research · Charlotte, United States
  • Centro de Investigaciones Reumatologicas · San Miguel de Tucumán, Argentina
  • Sunshine Coast University Private Hospital · Birtinya, Australia
  • El Centro de Estudios Reumatologicos (CER) · Providencia, Chile
  • Estudios Clinicos CTR · Santiago, Chile
  • Clinica Dermacross S.A. · Santiago, Chile
  • Sun Yat-sen University - The Third Affiliated Hospital · Guangzhou, China
  • Shenzhen People's Hospital · Shenzhen, China
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
  • The First Peoples Hospital - Changzhou (The Third Affiliated Hospital of Suzhou University) · Hangzhou, China
  • Shanxi Academy of Medical Sciences - Shanxi Bethune Hospital (Shanxi Dayi Hospital) · Taiyuan, China
  • Medicinski Centar Kuna and Peric · Zagreb, Croatia
  • CLINTRIAL s.r.o. · Prague, Czechia
  • Center for Clinical and Basic Research · Tallinn, Estonia
  • Porcika Klinika · Hódmezővásárhely, Hungary
  • Complex Rendelő Med Zrt · Székesfehérvár, Hungary
  • Azienda Ospedaliero-Universitaria delle Marche · Torrette, Italy
  • Tohoku University Hospital · Sendai, Japan
  • Toho University Ohashi Medical Center · Meguro-ku, Japan
  • Aotearoa Clinical Trials · Auckland, New Zealand
  • Nszoz Unica Cr · Dąbrówka, Poland
  • Centrum Medyczne Plejady · Krakow, Poland
  • Krakowskie Centrum Medyczne · Krakow, Poland
  • Santa Sp. z o.o. Santa Familia PTG Łódź · Lodz, Poland
  • ETYKA Osrodek Badan Klinicznych · Olsztyn, Poland
  • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
  • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
  • …and 3 more on the registry record
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    33 sites added — first sites in Argentina, Chile, Italy and United Kingdom
    Show 33 added (5 China, 5 Poland, 4 United States, 3 Chile, 3 Spain, 2 Hungary, 2 Japan, 1 Argentina, 1 Australia, 1 Croatia, 1 Czechia, 1 Estonia, 1 Italy, 1 New Zealand, 1 Taiwan, 1 United Kingdom)
    • Bioresearch Partners · Miami, United States
    • Clinical Research of West Florida | Tampa · Tampa, United States
    • Michigan Rheumatology Group, P.C. - Grand Blanc Office · Grand Blanc, United States
    • DJL Clinical Research · Charlotte, United States
    • Centro de Investigaciones Reumatologicas · San Miguel de Tucumán, Argentina
    • Sunshine Coast University Private Hospital · Birtinya, Australia
    • El Centro de Estudios Reumatologicos (CER) · Providencia, Chile
    • Estudios Clinicos CTR · Santiago, Chile
    • Clinica Dermacross S.A. · Santiago, Chile
    • Sun Yat-sen University - The Third Affiliated Hospital · Guangzhou, China
    • Shenzhen People's Hospital · Shenzhen, China
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    • The First Peoples Hospital - Changzhou (The Third Affiliated Hospital of Suzhou University) · Hangzhou, China
    • Shanxi Academy of Medical Sciences - Shanxi Bethune Hospital (Shanxi Dayi Hospital) · Taiyuan, China
    • Medicinski Centar Kuna and Peric · Zagreb, Croatia
    • CLINTRIAL s.r.o. · Prague, Czechia
    • Center for Clinical and Basic Research · Tallinn, Estonia
    • Porcika Klinika · Hódmezővásárhely, Hungary
    • Complex Rendelő Med Zrt · Székesfehérvár, Hungary
    • Azienda Ospedaliero-Universitaria delle Marche · Torrette, Italy
    • Tohoku University Hospital · Sendai, Japan
    • Toho University Ohashi Medical Center · Meguro-ku, Japan
    • Aotearoa Clinical Trials · Auckland, New Zealand
    • Nszoz Unica Cr · Dąbrówka, Poland
    • Centrum Medyczne Plejady · Krakow, Poland
    • Krakowskie Centrum Medyczne · Krakow, Poland
    • Santa Sp. z o.o. Santa Familia PTG Łódź · Lodz, Poland
    • ETYKA Osrodek Badan Klinicznych · Olsztyn, Poland
    • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
    • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
    • …and 3 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07286058
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Mar 11, 2026
Primary completion
Dec 18, 2029 (estimated)
Completion
Dec 18, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion